Evidence map›Paper›PMID 35221084›Full record

ReviewCardiac electrophysiology clinics2022

Clinical Features and Management of COVID-19-Associated Hypercoagulability.

Gianluca Massaro, Dalgisio Lecis, Eugenio Martuscelli, Gaetano Chiricolo, Giuseppe Massimo Sangiorgi

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cardiac electrophysiology clinics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Gianluca MassaroDivision of Cardiology, "Tor Vergata" University Hospital, v.le Oxford 81, Rome 00133, Italy.
Dalgisio LecisDivision of Cardiology, "Tor Vergata" University Hospital, v.le Oxford 81, Rome 00133, Italy.
Eugenio MartuscelliDivision of Cardiology, "Tor Vergata" University Hospital, v.le Oxford 81, Rome 00133, Italy; Department of Biomedicine and Prevention, "Tor Vergata" University of Rome, Rome 00133, Italy.
Gaetano ChiricoloDivision of Cardiology, "Tor Vergata" University Hospital, v.le Oxford 81, Rome 00133, Italy; Department of Biomedicine and Prevention, "Tor Vergata" University of Rome, Rome 00133, Italy. Electronic address: nucciochiricolo@gmail.com.
Giuseppe Massimo SangiorgiDivision of Cardiology, "Tor Vergata" University Hospital, v.le Oxford 81, Rome 00133, Italy; Department of Biomedicine and Prevention, "Tor Vergata" University of Rome, Rome 00133, Italy.
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is an acute respiratory disease of viral origin caused by SARS-CoV-2. This disease is associated with a hypercoagulable state resulting in arterial and venous thrombotic events. The latter are more frequent, especially in patients who develop a severe form of the disease and are associated with an increased mortality rate. It is therefore essential to identify patients at higher risk to initiate antithrombotic therapy. Hospitalized patients treated with treatment dose of anticoagulants had better outcomes than those treated with prophylactic dose. However, several trials are ongoing to better define the therapeutic and prevention strategies for this insidious complication.

Indexed as

COVID-19ThrombophiliaThrombosisAnticoagulantsHumansSARS-CoV-2AnticoagulantsAntithrombotic therapyArterial thrombosisCOVID-19 coagulopathyHypercoagulabilityVenous thromboembolism

Identifiers

PMID35221084
PMCPMC8556574
OpenAlexW3209693013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.